Crinetics Pharmaceuticals to Host Investor Call on January 5th, 2026, to Discuss PALSONIFY Commercialization and Atumelnant Phase 2 Data
SAN DIEGO, Jan. 04, 2026 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a biopharmaceutical company focused on transforming the treatment of endocrine diseases, announced today it will host a live conference call and webcast on Monday, January 5, 2026, at 8:30 a.m. Eastern Time. The event is slated to provide a comprehensive update on the commercialization strategy for PALSONIFY™ (paltusotine) and reveal topline results from the fourth cohort of the ongoing Phase 2 trial evaluating atumelnant for congenital adrenal hyperplasia (CAH).
The company’s management team will deliver prepared remarks, followed by a live question-and-answer session, offering investors and analysts an opportunity to engage directly with the leadership.
This investor event is strategically timed to coincide with a critical juncture for the company. The upcoming discussion on PALSONIFY’s commercialization will shed light on Crinetics’ go-to-market strategy for this potentially significant therapeutic. PALSONIFY, also known as paltusotine, has already received U.S. FDA approval for adults with acromegaly who have an inadequate response to surgery or for whom surgery is not an option. Its development is also progressing for carcinoid syndrome linked to neuroendocrine tumors, signaling a broader application within the endocrine disorder space.
Furthermore, the disclosure of topline data from the fourth cohort of the atumelnant Phase 2 trial in congenital adrenal hyperplasia is of considerable interest. Atumelnant is a key late-stage investigational candidate in Crinetics’ pipeline, also under development for ACTH-dependent Cushing’s syndrome. Positive results from this cohort could further de-risk the asset and bolster confidence in its potential for regulatory approval and market penetration in the treatment of CAH, a group of inherited disorders affecting the adrenal glands and hormone balance. The company’s scientific approach, focused on small molecules targeting G-protein coupled receptors (GPCRs), provides a strong foundation for developing differentiated therapies.
The market will be keenly observing the continuity of biomarker and symptom data from this atumelnant cohort compared to previous findings. Any commentary on the trajectory of clinical development, including potential next steps for atumelnant and its positioning against existing or emerging therapies, will be crucial. Investors will also be looking for management’s perspective on the overall pipeline strategy, especially concerning CRN09682, another promising candidate targeting neuroendocrine tumors and other solid tumors.
Crinetics has demonstrated a consistent track record of achieving clinical and corporate milestones, contributing to positive market sentiment. Recent events include the initiation of the Phase 3 CALM-CAH trial for atumelnant and the randomization of the first patient in the pivotal Phase 3 CAREFNDR trial for paltusotine in carcinoid syndrome. These developments underscore the company’s commitment to advancing its diverse portfolio.
An archived webcast of the event will be made available on the Events & Presentations page within the Investors section of the Crinetics website at www.crinetics.com/events following the live broadcast.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a global biopharmaceutical company dedicated to revolutionizing the treatment landscape for endocrine diseases and related tumors. Leveraging a deep scientific expertise in GPCR-targeted small molecules, Crinetics aims to discover, develop, and commercialize novel therapies that address significant unmet patient needs. The company’s robust pipeline includes approved therapies and late-stage investigational assets targeting conditions such as acromegaly, carcinoid syndrome, congenital adrenal hyperplasia, and Cushing’s syndrome, alongside a broad range of other endocrine disorders.
Investors can access the live audio-only webcast by dialing 1-833-470-1428 (domestic) or 1-646-844-6383 (international), referencing Access Code 640078.
This announcement comes amid a backdrop of significant activity in the rare disease and endocrinology therapeutic areas, where innovation can lead to substantial market opportunities and improved patient outcomes. Crinetics’ strategic updates are expected to provide key insights into the company’s progress and future prospects in these specialized markets.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/15302.html
